Literature DB >> 23255232

High-mobility group box 2 (HMGB2) modulates radioresponse and is downregulated by p53 in colorectal cancer cell.

Young-Joo Shin1, Mi-Sook Kim, Moon-Sun Kim, Joonseok Lee, Miae Kang, Jae-Hoon Jeong.   

Abstract

Overexpression of high-mobility group box 2 (HMGB2) is recently reported in several malignant cancers and was correlated with poor response to preoperative chemoradiotherapy of colorectal cancer patients. To enhance the chemoradiotherapy efficacy, the biological function of HMGB2 was investigated with respect to radiation response. HMGB2 gene knockdown cells were constructed by infecting shRNA expressing lentivirus and clonogenic assay was performed to count the radiosensitivity. HMGB2 knockdown sensitized HCT-116 and HT-29 colorectal cancer cells to ionizing radiation. This could be due to an increased DNA damage and an inefficient DNA damage repair in HMGB2 knockdown cells. In addition, an exposure to radiation downregulated HMGB2 expression in colorectal cancer cells with an intact TP53 gene. HMGB2 gene expression of TP53-mutant cell was not affected by irradiation. p53-mediated downregulation of HMGB2 was confirmed by direct activation of p53 using Nutlin-3 or by inducing p53 expression using Tet-On system. Luciferase reporter assay showed that HMGB2 promoter activity was inversely correlated with the amount p53 cotransfected. Our study revealed that HMGB2 is necessary to protect colorectal cancer cells from DNA damage and efficient DNA repair and p53-mediated downregulation is a critical mechanism of modulating HMGB2 expression.

Entities:  

Keywords:  DNA damage; HMGB2; colorectal cancer; p53; radiation

Mesh:

Substances:

Year:  2012        PMID: 23255232      PMCID: PMC3595303          DOI: 10.4161/cbt.23292

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  38 in total

Review 1.  HMGB proteins and gene expression.

Authors:  Alessandra Agresti; Marco E Bianchi
Journal:  Curr Opin Genet Dev       Date:  2003-04       Impact factor: 5.578

Review 2.  Priming the nucleosome: a role for HMGB proteins?

Authors:  Andrew A Travers
Journal:  EMBO Rep       Date:  2003-02       Impact factor: 8.807

Review 3.  Live or let die: the cell's response to p53.

Authors:  Karen H Vousden; Xin Lu
Journal:  Nat Rev Cancer       Date:  2002-08       Impact factor: 60.716

4.  Clonogenic cell survival assay.

Authors:  Anupama Munshi; Marvette Hobbs; Raymond E Meyn
Journal:  Methods Mol Med       Date:  2005

5.  Adjuvant radiotherapy for rectal cancer: a systematic overview of 8,507 patients from 22 randomised trials.

Authors: 
Journal:  Lancet       Date:  2001-10-20       Impact factor: 79.321

6.  HMGB1 and HMGB2 cell-specifically down-regulate the p53- and p73-dependent sequence-specific transactivation from the human Bax gene promoter.

Authors:  Michal Stros; Toshinori Ozaki; Alena Bacikova; Hajime Kageyama; Akira Nakagawara
Journal:  J Biol Chem       Date:  2001-12-17       Impact factor: 5.157

7.  Steroid hormones induce HMG1 overexpression and sensitize breast cancer cells to cisplatin and carboplatin.

Authors:  Q He; C H Liang; S J Lippard
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

Review 8.  TP53 mutation in colorectal cancer.

Authors:  Barry Iacopetta
Journal:  Hum Mutat       Date:  2003-03       Impact factor: 4.878

9.  A nuclear protein complex containing high mobility group proteins B1 and B2, heat shock cognate protein 70, ERp60, and glyceraldehyde-3-phosphate dehydrogenase is involved in the cytotoxic response to DNA modified by incorporation of anticancer nucleoside analogues.

Authors:  Eugene Y Krynetski; Natalia F Krynetskaia; Marco E Bianchi; William E Evans
Journal:  Cancer Res       Date:  2003-01-01       Impact factor: 12.701

10.  Reduced fertility and spermatogenesis defects in mice lacking chromosomal protein Hmgb2.

Authors:  L Ronfani; M Ferraguti; L Croci; C E Ovitt; H R Schöler; G G Consalez; M E Bianchi
Journal:  Development       Date:  2001-04       Impact factor: 6.868

View more
  14 in total

1.  Dynamic expression of ZNF382 and its tumor-suppressor role in hepatitis B virus-related hepatocellular carcinogenesis.

Authors:  Siwen Dang; Jingshi Zhou; Yijun Chen; Pu Chen; Meiju Ji; Bingyin Shi; Qi Yang; Peng Hou
Journal:  Oncogene       Date:  2019-02-25       Impact factor: 9.867

2.  Long non-coding RNA HNF1A-AS1 regulates proliferation and migration in oesophageal adenocarcinoma cells.

Authors:  Xue Yang; Jee Hoon Song; Yulan Cheng; Wenjing Wu; Tushar Bhagat; Yiting Yu; John M Abraham; Sariat Ibrahim; William Ravich; Bani Chander Roland; Mouen Khashab; Vikesh K Singh; Eun Ji Shin; Xiao Yang; Amit K Verma; Stephen J Meltzer; Yuriko Mori
Journal:  Gut       Date:  2013-09-02       Impact factor: 23.059

3.  Identification of commonly dysregulated genes in colorectal cancer by integrating analysis of RNA-Seq data and qRT-PCR validation.

Authors:  W H Xiao; X L Qu; X M Li; Y L Sun; H X Zhao; S Wang; X Zhou
Journal:  Cancer Gene Ther       Date:  2015-04-24       Impact factor: 5.987

4.  Centromere protein U facilitates metastasis of ovarian cancer cells by targeting high mobility group box 2 expression.

Authors:  Hongjuan Li; Hui Zhang; Yali Wang
Journal:  Am J Cancer Res       Date:  2018-05-01       Impact factor: 6.166

Review 5.  The role of high mobility group protein B3 (HMGB3) in tumor proliferation and drug resistance.

Authors:  Bin Wen; Ying-Ting Wei; Kui Zhao
Journal:  Mol Cell Biochem       Date:  2021-01-11       Impact factor: 3.396

6.  Silencing of high-mobility group box 2 (HMGB2) modulates cisplatin and 5-fluorouracil sensitivity in head and neck squamous cell carcinoma.

Authors:  Nazia Syed; Sandip Chavan; Nandini A Sahasrabuddhe; Santosh Renuse; Gajanan Sathe; Vishalakshi Nanjappa; Aneesha Radhakrishnan; Remya Raja; Sneha M Pinto; Anand Srinivasan; T S Keshava Prasad; Kotteazeth Srikumar; Harsha Gowda; Vani Santosh; David Sidransky; Joseph A Califano; Akhilesh Pandey; Aditi Chatterjee
Journal:  Proteomics       Date:  2015-01       Impact factor: 3.984

7.  Targeting the High-Mobility Group Box 3 Protein Sensitizes Chemoresistant Ovarian Cancer Cells to Cisplatin.

Authors:  Anirban Mukherjee; Van Huynh; Kailee Gaines; Wade Alan Reh; Karen M Vasquez
Journal:  Cancer Res       Date:  2019-05-06       Impact factor: 12.701

8.  STING protects breast cancer cells from intrinsic and genotoxic-induced DNA instability via a non-canonical, cell-autonomous pathway.

Authors:  Stefano Cairo; Vincent Goffin; Laura Cheradame; Ida Chiara Guerrera; Julie Gaston; Alain Schmitt; Vincent Jung; Nicolas Goudin; Marion Pouillard; Nina Radosevic-Robin; Mauro Modesti; Jean-Gabriel Judde
Journal:  Oncogene       Date:  2021-10-08       Impact factor: 9.867

Review 9.  Targeting Chromosomal Architectural HMGB Proteins Could Be the Next Frontier in Cancer Therapy.

Authors:  Anirban Mukherjee; Karen M Vasquez
Journal:  Cancer Res       Date:  2020-03-09       Impact factor: 12.701

10.  Specific TP53 Mutants Overrepresented in Ovarian Cancer Impact CNV, TP53 Activity, Responses to Nutlin-3a, and Cell Survival.

Authors:  Lisa K Mullany; Kwong-Kwok Wong; David C Marciano; Panagiotis Katsonis; Erin R King-Crane; Yi Athena Ren; Olivier Lichtarge; JoAnne S Richards
Journal:  Neoplasia       Date:  2015-10       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.